Opportunities to Improve Glaucoma Treatment
The goal of most glaucoma treatments is to lower eye pressure more effectively or more safely for longer periods of time.
A new molecular class of drugs, rho kinase (ROCK) inhibitors, is in development for the treatment of glaucoma patients. With minimal systemic side effects and tolerable ocular side effects, ROCK inhibitors have no contraindications - thus offering doctors and patients a necessary treatment option with convenient, once-a-day dosing.
Learn more about how this class fits into the timeline of advances in glaucoma treatment, and the potential that ROCK inhibitors may hold.
Read the Whitepaper now
Common Virus Improves Melanoma Treatment Response, Reduces Side Effects
May 9th 2025Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started immunotherapy. This may be one reason why these patients responded better to certain immunotherapy treatments, researchers said.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, six additional CAR-T cell therapies have been introduced to the market. Four of the seven are approved for B-cell lymphomas.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
